<div id="readability-page-1"><div><ul><li>Instil Bio Inc is expected to show no change in quarterly revenue when it reports results on November 11 (estimated) for the period ending September 30 2025</li><li></li><li>​LSEG's mean analyst estimate for Instil Bio Inc is for a loss of $2.35 per share. </li><li>The current average analyst rating on the shares is &#34;buy&#34; and the breakdown of recommendations is 3 &#34;strong buy&#34; or &#34;buy,&#34; 1 &#34;hold&#34; and no &#34;sell&#34; or &#34;strong sell.&#34; </li><li>The mean earnings estimate of analysts was unchanged in the last three months. ​</li><li>Wall Street's median 12-month price target for Instil Bio Inc is $88.00, about 82.9% above its last closing price of $15.02</li></ul>Previous quarterly performance (using preferred earnings measure in US dollars). ​<div><table><tbody><tr><td>QUARTER ENDING</td><td>STARMINESMARTESTIMATE®</td><td>LSEG IBES ESTIMATE </td><td>ACTUAL</td><td>BEAT, MET, MISSED</td><td>SURPRISE %</td></tr><tr><td>Jun. 30 2025</td><td>-2.92</td><td>-2.50</td><td>-3.24</td><td>Missed</td><td>-29.5</td></tr><tr><td>Mar. 31 2025</td><td>-2.74</td><td>-2.59</td><td>-4.32</td><td>Missed</td><td>-67</td></tr><tr><td>Dec. 31 2024</td><td>-3.26</td><td>-3.22</td><td>-1.82</td><td>Beat</td><td>43.5​</td></tr><tr><td>Sep. 30 2024</td><td>-2.33</td><td>-2.11</td><td>-3.54</td><td>Missed</td><td>-68</td></tr><tr><td>​​Jun. 30 2024</td><td>-2.99</td><td>-2.98</td><td>-2.29</td><td>Beat</td><td>23.2</td></tr><tr><td>Mar. 31 2024</td><td>-2.22</td><td>-2.23</td><td>-3.74</td><td>Missed</td><td>-67.7​</td></tr><tr><td>Dec. 31 2023</td><td>-2.29</td><td>-2.84</td><td>-1.99</td><td>Beat</td><td>30.1</td></tr><tr><td>Sep. 30 2023</td><td>-1.98</td><td>-2.00</td><td>-10.40</td><td>Missed</td><td>-420</td></tr></tbody></table></div>This summary was machine generated November 7 at 16:43 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</div></div>

Instil Bio Inc is expected to report a loss of $2.35 per share for the quarter ending September 30, 2025, with no change in quarterly revenue. The average analyst rating is "buy," with a median 12-month price target of $88.00, significantly above its last closing price of $15.02. Previous earnings reports show mixed results, with several misses and a few beats in the last quarters. The mean earnings estimate has remained unchanged over the last three months.

Instil Bio Inc expected to post a loss of $2.35 a share - Earnings Preview